Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Journal of Behavioral Medicine 3/2010

01-06-2010

Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition

Auteurs: Jared M. Bruce, Laura M. Hancock, Peter Arnett, Sharon Lynch

Gepubliceerd in: Journal of Behavioral Medicine | Uitgave 3/2010

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

The purpose of the present study was to prospectively examine the association between treatment adherence and common neuropsychiatric symptoms in multiple sclerosis (MS). Patients underwent a thorough psychiatric and neuropsychological evaluation at the outset of the study. Patient adherence to disease modifying therapies was then tracked for 8 weeks using self-report, a medication diary, and an electronic monitoring device that recorded needle disposals. Results indicated that MS patients with current mood or anxiety disorders were almost five times as likely as MS patients with no psychiatric diagnosis to exhibit problems adhering to their disease modifying therapies. Poor adherence was also associated with memory difficulties, anxiety, depression, neuroticism, and low conscientiousness. Findings highlight the importance of conducting a thorough psychiatric and neuropsychological evaluation when clinicians suspect poor adherence to disease modifying therapies. Pharmacological or psychotherapeutic treatment of mood/anxiety disorders, use of scheduled reminders, and/or increased organization and structure may lead to improved treatment adherence in MS.
Literatuur
go back to reference Albert, S. M., Flater, S. R., Clouse, R., Todak, G., Stern, Y., & Marder, K. (2003). Medication management skill in HIV: I. Evidence for adaptation of medication management strategies in people with cognitive impairment. II. Evidence for a pervasive lay model of medication efficacy. AIDS and Behavior, 7(3), 329–338. CrossRefPubMed Albert, S. M., Flater, S. R., Clouse, R., Todak, G., Stern, Y., & Marder, K. (2003). Medication management skill in HIV: I. Evidence for adaptation of medication management strategies in people with cognitive impairment. II. Evidence for a pervasive lay model of medication efficacy. AIDS and Behavior, 7(3), 329–338. CrossRefPubMed
go back to reference Altice, F., & Friedland, G. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129, 503–505. PubMed Altice, F., & Friedland, G. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129, 503–505. PubMed
go back to reference Arnett, P. A. (2003). Neuropsychological presentation and treatment of demyelinating disorders. In U. K. P. Halligan & J. Marshall (Eds.), Handbook of Clinical Neuropsychology (pp. 528–543). Oxford: Oxford University Press. Arnett, P. A. (2003). Neuropsychological presentation and treatment of demyelinating disorders. In U. K. P. Halligan & J. Marshall (Eds.), Handbook of Clinical Neuropsychology (pp. 528–543). Oxford: Oxford University Press.
go back to reference Beck, A. T., Steer, R. A., & Brown, G. K. (2000). BDI-FastScreen for Medical Patients Manual. San Antonio: The Psychological Corporation. Beck, A. T., Steer, R. A., & Brown, G. K. (2000). BDI-FastScreen for Medical Patients Manual. San Antonio: The Psychological Corporation.
go back to reference Benedict, R. H., Fishman, I., McClellan, M. M., Bakshi, R., & Weinstock-Guttman, B. (2003). Validity of the beck depression inventory-fast screen in multiple sclerosis. Multiple Sclerosis, 9(4), 393–396. CrossRefPubMed Benedict, R. H., Fishman, I., McClellan, M. M., Bakshi, R., & Weinstock-Guttman, B. (2003). Validity of the beck depression inventory-fast screen in multiple sclerosis. Multiple Sclerosis, 9(4), 393–396. CrossRefPubMed
go back to reference Benedict, R. H. B., Priore, R. L., Miller, C., Munschauer, F., & Jacobs, L. (2001). Personality disorder in multiple sclerosis correlates with cognitive impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 13, 70–76. PubMed Benedict, R. H. B., Priore, R. L., Miller, C., Munschauer, F., & Jacobs, L. (2001). Personality disorder in multiple sclerosis correlates with cognitive impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 13, 70–76. PubMed
go back to reference Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of Neurological Sciences, 231(1–2), 29–34. CrossRef Benedict, R. H. B., Wahlig, E., Bakshi, R., Fishman, I., Munschauer, F., Zivadinov, R., et al. (2005). Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. Journal of Neurological Sciences, 231(1–2), 29–34. CrossRef
go back to reference Berger, B. A., Hudmon, K. S., & Liang, H. (2004). Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. Journal of the American Pharmacists Association, 44(4), 445–454. CrossRefPubMed Berger, B. A., Hudmon, K. S., & Liang, H. (2004). Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. Journal of the American Pharmacists Association, 44(4), 445–454. CrossRefPubMed
go back to reference Bosworth, H. (2006). Medication Treatment Adherence. In H. Bosworth, E. Oddone, & M. Weinberger (Eds.), Patient Treatment Adherence: Concepts Interventions, and Measurement. London: Lawrence Erlbaum Associates. Bosworth, H. (2006). Medication Treatment Adherence. In H. Bosworth, E. Oddone, & M. Weinberger (Eds.), Patient Treatment Adherence: Concepts Interventions, and Measurement. London: Lawrence Erlbaum Associates.
go back to reference Brauner, D., Muir, C., & Sachs, G. (2000). Treating nondementia illnesses in patients with dementia. Journal of the American Medical Association, 283(24), 3230–3235. CrossRefPubMed Brauner, D., Muir, C., & Sachs, G. (2000). Treating nondementia illnesses in patients with dementia. Journal of the American Medical Association, 283(24), 3230–3235. CrossRefPubMed
go back to reference Bruce, J. M., & Arnett, P. (2009). Clinical correlates of generalized worry in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 31(6), 698–705. CrossRefPubMed Bruce, J. M., & Arnett, P. (2009). Clinical correlates of generalized worry in multiple sclerosis. Journal of Clinical and Experimental Neuropsychology, 31(6), 698–705. CrossRefPubMed
go back to reference Bruce, J. M., Hancock, L., Lynch, S. (2010). Objective adherence monitoring in MS: Initial validation and association with self-report. Multiple Sclerosis, 16(1), 112–120. CrossRefPubMed Bruce, J. M., Hancock, L., Lynch, S. (2010). Objective adherence monitoring in MS: Initial validation and association with self-report. Multiple Sclerosis, 16(1), 112–120. CrossRefPubMed
go back to reference Costa, P. T., & McCrae, R. R. (1992). Professional manual for the NEO PI-R and NEO-FFI.: Psychological Assessment Resources. Costa, P. T., & McCrae, R. R. (1992). Professional manual for the NEO PI-R and NEO-FFI.: Psychological Assessment Resources.
go back to reference Cramer, J. (2004). A systematic review of adherence with medications for diabetes. Diabetes Care, 27(5), 1218–1224. CrossRefPubMed Cramer, J. (2004). A systematic review of adherence with medications for diabetes. Diabetes Care, 27(5), 1218–1224. CrossRefPubMed
go back to reference Edwards, G. J. B., Leffler, D. A., Dennis, M. D., Franko, D. L., Blom-Hoffman, J., & Kelly, C. P. (2009). Psychological correlates of gluten free diet adherence in adults with celiac disease. Journal of Clinical Gastroenterology, 43(4), 301–306. CrossRef Edwards, G. J. B., Leffler, D. A., Dennis, M. D., Franko, D. L., Blom-Hoffman, J., & Kelly, C. P. (2009). Psychological correlates of gluten free diet adherence in adults with celiac disease. Journal of Clinical Gastroenterology, 43(4), 301–306. CrossRef
go back to reference Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9–14. PubMed Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9–14. PubMed
go back to reference Fraser, C., Morgante, L., Hadjimichael, O., & Vollmer, T. (2004). A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. Journal of Neuroscience Nursing, 36(3), 120–129. CrossRefPubMed Fraser, C., Morgante, L., Hadjimichael, O., & Vollmer, T. (2004). A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis. Journal of Neuroscience Nursing, 36(3), 120–129. CrossRefPubMed
go back to reference Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology, 71(24 Suppl 3), S8–S13. CrossRefPubMed Goodin, D. S. (2008). Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology, 71(24 Suppl 3), S8–S13. CrossRefPubMed
go back to reference Grant, D. A., & Berg, E. A. (1948). A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem. Journal of Experimental Psychology, 38(4), 404–411. CrossRefPubMed Grant, D. A., & Berg, E. A. (1948). A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem. Journal of Experimental Psychology, 38(4), 404–411. CrossRefPubMed
go back to reference Haas, J., & Firzlaff, M. (2005). Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology, 12(6), 425–431. CrossRefPubMed Haas, J., & Firzlaff, M. (2005). Twenty-four-month comparison of immunomodulatory treatments—a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology, 12(6), 425–431. CrossRefPubMed
go back to reference Higginson, C. I., Arnett, P. A., & Voss, W. D. (2000). The ecological validity of clinical tests of memory and attention in multiple sclerosis. Archives of Clinical Neuropsychology, 15, 185–204. PubMed Higginson, C. I., Arnett, P. A., & Voss, W. D. (2000). The ecological validity of clinical tests of memory and attention in multiple sclerosis. Archives of Clinical Neuropsychology, 15, 185–204. PubMed
go back to reference Insel, K., Morrow, D., Brewer, B., & Figueredo, A. (2006). Executive function, working memory, and medication adherence among older adults. Journal of Gerontology Series B: Psychological Sciences and Social Sciences, 61(2), P102–P107. Insel, K., Morrow, D., Brewer, B., & Figueredo, A. (2006). Executive function, working memory, and medication adherence among older adults. Journal of Gerontology Series B: Psychological Sciences and Social Sciences, 61(2), P102–P107.
go back to reference Inui, T. S., Carter, W. B., & Pecoraro, R. E. (1981). Screening for noncompliance among patients with hypertension: is self-report the best available measure? Medical Care, 19(10), 1061–1064. CrossRefPubMed Inui, T. S., Carter, W. B., & Pecoraro, R. E. (1981). Screening for noncompliance among patients with hypertension: is self-report the best available measure? Medical Care, 19(10), 1061–1064. CrossRefPubMed
go back to reference Korostil, M., & Feinstein, A. (2007). Anxiety disorders and their clinical correlates in multiple sclerosis patients. Multiple Sclerosis, 13(1), 67–72. CrossRefPubMed Korostil, M., & Feinstein, A. (2007). Anxiety disorders and their clinical correlates in multiple sclerosis patients. Multiple Sclerosis, 13(1), 67–72. CrossRefPubMed
go back to reference Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33, 1444–1452. PubMed Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33, 1444–1452. PubMed
go back to reference Lezak, M. (1995). Neuropsychological assessment, third edition (3rd ed.). New York: Oxford University Press. Lezak, M. (1995). Neuropsychological assessment, third edition (3rd ed.). New York: Oxford University Press.
go back to reference Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968–977. PubMed Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134(10), 968–977. PubMed
go back to reference Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911. PubMed Lublin, F. D., & Reingold, S. C. (1996). Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology, 46, 907–911. PubMed
go back to reference Milanese, C., La Mantia, L., Palumbo, R., Martinelli, V., Murialdo, A., Zaffaroni, M., et al. (2003). A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. Journal of Neurology, Neurosurgery and Psychiatry, 74(12), 1689–1692. CrossRef Milanese, C., La Mantia, L., Palumbo, R., Martinelli, V., Murialdo, A., Zaffaroni, M., et al. (2003). A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. Journal of Neurology, Neurosurgery and Psychiatry, 74(12), 1689–1692. CrossRef
go back to reference Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23(2), 125–132. CrossRefPubMed Mohr, D. C., Boudewyn, A. C., Likosky, W., Levine, E., & Goodkin, D. E. (2001). Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine, 23(2), 125–132. CrossRefPubMed
go back to reference Mohr, D., & Cox, D. (2001). Multiple sclerosis: empirical literature for the clinical health psychologist. Journal of Clinical Psychology, 57(4), 479–499. CrossRefPubMed Mohr, D., & Cox, D. (2001). Multiple sclerosis: empirical literature for the clinical health psychologist. Journal of Clinical Psychology, 57(4), 479–499. CrossRefPubMed
go back to reference Newby, L., LaPointe, N., Chen, A., Kramer, J., Hammill, B., DeLong, E., et al. (2006). Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 113, 203–212. CrossRefPubMed Newby, L., LaPointe, N., Chen, A., Kramer, J., Hammill, B., DeLong, E., et al. (2006). Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 113, 203–212. CrossRefPubMed
go back to reference O’Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis, 11(1), 46–50. CrossRefPubMed O’Rourke, K. E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis, 11(1), 46–50. CrossRefPubMed
go back to reference Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2002). Patient adherence in the treatment of depression. British Journal of Psychiatry, 180, 104–109. CrossRefPubMed Pampallona, S., Bollini, P., Tibaldi, G., Kupelnick, B., & Munizza, C. (2002). Patient adherence in the treatment of depression. British Journal of Psychiatry, 180, 104–109. CrossRefPubMed
go back to reference Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology, 58(6), 840–846. CrossRefPubMed Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology, 58(6), 840–846. CrossRefPubMed
go back to reference Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S., & Amato, M. P. (2008). Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. European Neurology, 59(3–4), 131–135. CrossRefPubMed Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S., & Amato, M. P. (2008). Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. European Neurology, 59(3–4), 131–135. CrossRefPubMed
go back to reference Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991a). Cognitive dysfunction in multiple sclerosis. 1. Frequency, patterns, and prediction. Neurology, 41, 685–691. PubMed Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991a). Cognitive dysfunction in multiple sclerosis. 1. Frequency, patterns, and prediction. Neurology, 41, 685–691. PubMed
go back to reference Rao, S. M., Leo, G. J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991b). Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 41, 692–696. PubMed Rao, S. M., Leo, G. J., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991b). Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology, 41, 692–696. PubMed
go back to reference Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11(3), 306–309. CrossRefPubMed Rio, J., Porcel, J., Tellez, N., Sanchez-Betancourt, A., Tintore, M., Arevalo, M. J., et al. (2005). Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis, 11(3), 306–309. CrossRefPubMed
go back to reference Ruggieri, R. M., Settipani, N., Viviano, L., Attanasio, M., Giglia, L., Almasio, P., et al. (2003). Long-term interferon-beta treatment for multiple sclerosis. Neurological Science, 24(5), 361–364. CrossRef Ruggieri, R. M., Settipani, N., Viviano, L., Attanasio, M., Giglia, L., Almasio, P., et al. (2003). Long-term interferon-beta treatment for multiple sclerosis. Neurological Science, 24(5), 361–364. CrossRef
go back to reference Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(20), 22–33. PubMed Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(20), 22–33. PubMed
go back to reference Smith, A. (1982). Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles: Western Psychological Services. Smith, A. (1982). Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles: Western Psychological Services.
go back to reference Spielberger, C. D. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press. Spielberger, C. D. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press.
go back to reference Stein, M., Cantrell, C., Sokol, M., Eaddy, M., & Shah, M. (2006). Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatric Services, 57(5), 673–680. CrossRefPubMed Stein, M., Cantrell, C., Sokol, M., Eaddy, M., & Shah, M. (2006). Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatric Services, 57(5), 673–680. CrossRefPubMed
go back to reference Stilley, C. S., Sereika, S., Muldoon, M. F., Ryan, C. M., & Dunbar-Jacob, J. (2004). Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Annals of Behavioral Medicine, 27(2), 117–124. CrossRefPubMed Stilley, C. S., Sereika, S., Muldoon, M. F., Ryan, C. M., & Dunbar-Jacob, J. (2004). Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Annals of Behavioral Medicine, 27(2), 117–124. CrossRefPubMed
go back to reference Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18, 643–662. CrossRef Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18, 643–662. CrossRef
go back to reference Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology, 61(4), 551–554. PubMed Tremlett, H. L., & Oger, J. (2003). Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology, 61(4), 551–554. PubMed
go back to reference Turner, A. P., Kivlahan, D. R., Sloan, A. P., & Haselkorn, J. K. (2007). Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Multiple Sclerosis, 13(9), 1146–1152. CrossRefPubMed Turner, A. P., Kivlahan, D. R., Sloan, A. P., & Haselkorn, J. K. (2007). Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Multiple Sclerosis, 13(9), 1146–1152. CrossRefPubMed
go back to reference Van Houtven, C., Weinberger, M., & Carey, T. (2006). Implications of nonadherence for economic evaluation and health policy. In H. Bosworth, E. Oddone, & M. Weinberger (Eds.), Patient Treatment Adherence: Concepts, Interventions, and Measurement. London: Lawrence Erlbaum Associates. Van Houtven, C., Weinberger, M., & Carey, T. (2006). Implications of nonadherence for economic evaluation and health policy. In H. Bosworth, E. Oddone, & M. Weinberger (Eds.), Patient Treatment Adherence: Concepts, Interventions, and Measurement. London: Lawrence Erlbaum Associates.
go back to reference Wechsler, D. (1997). Wechsler Adult Intelligence Scale (3rd ed.). San Antonio: The Psychological Corporation. Wechsler, D. (1997). Wechsler Adult Intelligence Scale (3rd ed.). San Antonio: The Psychological Corporation.
go back to reference Wetherell, J., & Unutzer, J. (2003). Adherence to treatment for geriatric depression and anxiety. CNS Spectrums, 8(12 supplement 3), 48–59. PubMed Wetherell, J., & Unutzer, J. (2003). Adherence to treatment for geriatric depression and anxiety. CNS Spectrums, 8(12 supplement 3), 48–59. PubMed
go back to reference Woods, S. P., Moran, L. M., Dawson, M. S., Carey, C. L., & Grant, I. (2008). Psychometric characteristics of the memory for intentions screening test. The Clinical Neuropsychologist, 22(5), 864–878. CrossRefPubMed Woods, S. P., Moran, L. M., Dawson, M. S., Carey, C. L., & Grant, I. (2008). Psychometric characteristics of the memory for intentions screening test. The Clinical Neuropsychologist, 22(5), 864–878. CrossRefPubMed
go back to reference World Health Organization. (2003). Adherence to Long-term Therapies: Evidence for Action. Geneva: WHO. World Health Organization. (2003). Adherence to Long-term Therapies: Evidence for Action. Geneva: WHO.
go back to reference Zeller, A., Ramseier, E., Teagtmeyer, A., & Battegay, E. (2008). Patients’ self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertension Research, 31(11), 2037–2043. CrossRefPubMed Zeller, A., Ramseier, E., Teagtmeyer, A., & Battegay, E. (2008). Patients’ self-reported adherence to cardiovascular medication using electronic monitors as comparators. Hypertension Research, 31(11), 2037–2043. CrossRefPubMed
Metagegevens
Titel
Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition
Auteurs
Jared M. Bruce
Laura M. Hancock
Peter Arnett
Sharon Lynch
Publicatiedatum
01-06-2010
Uitgeverij
Springer US
Gepubliceerd in
Journal of Behavioral Medicine / Uitgave 3/2010
Print ISSN: 0160-7715
Elektronisch ISSN: 1573-3521
DOI
https://doi.org/10.1007/s10865-010-9247-y

Andere artikelen Uitgave 3/2010

Journal of Behavioral Medicine 3/2010 Naar de uitgave